Generate QR code
Open Access
Subscription Access
Assessment of the effect of metabolic variables on the duration of progression-free survival in patients with lymphomas
https://doi.org/10.30629/0023-2149-2025-103-8-9-634-640
Abstract
In this study, the relationship between the results of positron emission tomography (PET) with fluorodeoxyglucose (FDG) in patients with lymphomas and their progression-free survival (PFS) was analyzed. The aim of the study was to determine whether there are differences in the level of FDH absorption and tumor volume in patients with different periods of PFS after treatment and a score of 3 points on the PET scale. The average values of FDG uptake and tumor volume in patients with different periods of AFD were calculated and compared. It was revealed that in patients with a period of PFS of more than 24 months, there are statistically significant differences in both parameters. These results can be used as an additional factor in predicting the disease in patients with lymphomas after treatment and a 3-point PET score.
About the Authors
S. A. Alekseev
Main Military Clinical Hospital named after Academician N.N. Burdenko of the Ministry of Defense of Russia
Россия
Россия
Sergey A. Alekseev — Candidate of Medical Sciences, Head of the CT and MRI Cabinet of the X-ray Department of the Center for Radiation Diagnostics
Moscow
V. N. Troyan
Main Military Clinical Hospital named after Academician N.N. Burdenko of the Ministry of Defense of Russia
Россия
Россия
Vladimir N. Troyan — Doctor of Medical Sciences, Professor, Head of the Center for Radiation Diagnostics
Moscow
O. A. Rukavitsyn
Main Military Clinical Hospital named after Academician N.N. Burdenko of the Ministry of Defense of Russia
Россия
Россия
Oleg A. Rukavitsyn — Doctor of Medical Sciences, Professor, Head of the Hematology Center
Moscow
References
1. Atabayeva A.K., Khismetova Z.A., Nurakhmetova Zh.B. Epidemiology of Neoplasms of the Blood System Literature Review. Science and Healthcare. 2021;23(6):188–197. (In Russian).
2. Galchenko L.I. Positron Emission Tomography in the Diagnosis and Evaluation of the Effectiveness of Treatment of Hodgkin’s Lymphoma. Medicine and High Technologies. 2022;3:51–57. (In Russian).
3. Golykh L.S. Hodgkin’s lymphoma. Russian Pediatric Journal. 2022;25(6):396–397. (In Russian).
4. Kalenik O.A. The Prognostic Value of the Completeness of the Metabolic Response in Patients With Diffuse B-Large Cell Lymphoma. Vesci National Academy Of Sciences Of Belarus. Gray Meditsynsky Navuk. 2023;20(1):7–16. (In Russian).
5. Baembaev F.A. Disadvantages of PET/CT examination in the diagnosis of lymphoproliferative diseases: A review of the literature. Oncology and Radiology of Kazakhstan. 2023;1(67):62–67. (In Russian).
6. Rukavitsyn О.A., Udalyeva V.Yu., Ageev T.A. Hematology. GEOTAR-Media Group, 2024:916. (In Russian). ISBN 978-5-9704-8188-2.
7. Blanc-Durand P. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network. European Journal of Nuclear Medicine and Molecular Imaging. 2021;48(5):1362–1370.
8. El-Galaly T.C., Gormsen L.C., Hutchings M. PET/CT for staging; past, present, and future. Seminars in Nuclear Medicine. 2018;48(1):4–16.
9. Herrmann K. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT. BMC cancer. 2015;15.
10. Efremova D.S. Nuclear Medicine and its prospects. Bulletin of Science. 2023;5(4(61)):437–445. (In Russian).
11. Barrington S.F. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology. 2014;32(27)3048–3058.
12. Cottereau A.S. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Annals of Oncology. 2016;27(4):719–724.
13. Aslanidis I.P. Volumetric Pet-Biomarkers in Hodgkin’s Lymphoma. The initial experience of automatic and manual methods of evaluation. Russian Electronic Journal of Radiology. 2022;12:80–88.
14. Jin X. Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2022;63(2):212–217.
15. Kobe C. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Seminars in Nuclear Medicine. 2018;48(1):28 –36. 16. Kwee T.C., Kwee R.M., Nievelstein R.A.J. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111(2):504– 516.
Review
For citations:
Alekseev S.A., Troyan V.N., Rukavitsyn O.A. Assessment of the effect of metabolic variables on the duration of progression-free survival in patients with lymphomas. Clinical Medicine (Russian Journal). 2025;103(8-9):634-640. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-8-9-634-640
Views:
19
JATS XML
Email this article 